ReWalk Robotics Reports Second Quarter 2017 Financial Results
Aug 03, 2017 11:30 am UTC| Business
-- 146% YOY growth in Q2 revenue to $2 million and record 1H revenue of $4.5 million – -- 11 favorable commercial case-by-case insurance coverage decisions -- -- 217 pending insurance claims in the U.S. and Germany -- --...
Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
Aug 03, 2017 11:30 am UTC| Business
On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis (non-CF) Bronchiectasis in...
DIA Elects Cancer Genetics, Inc.’s John A. (Jay) Roberts as Chairman of DIA Board of Directors
Aug 03, 2017 11:30 am UTC| Business
DIA is a professional community and knowledge exchange network for global health care product developmentMr. Roberts, who is also the Chief Operating Officer and EVP of Finance at Cancer Genetics, Inc. (Nasdaq:CGIX) will...
Adaptimmune Reports Second Quarter 2017 Financial Results
Aug 03, 2017 11:30 am UTC| Business
– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 – – Enrolling 9 clinical studies with NY-ESO as well...
Repligen Reports Second Quarter 2017 Financial Results
Aug 03, 2017 11:30 am UTC| Business
Record quarterly revenue of $32.5 millionFirst half 2017 revenue growth of 16% or 18% at constant currencyEnters agreement to acquire Spectrum, Inc., which closed August 1Prices follow-on offering which netted proceeds of...
Aug 03, 2017 11:30 am UTC| Business
BELGRADE, Mont., Aug. 03, 2017 -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, is proud to announce its sponsorship of the 2018...
Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
Aug 03, 2017 11:30 am UTC| Business
FDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second half of 2017 Amended...
Johannesburg in a time of darkness: Ivan Vladislavić’s new memoir reminds us of the city’s fragility
Economist Chris Richardson on an ‘ugly’ inflation result and the coming budget
The Mattei Plan: why Giorgia Meloni is looking to Africa
Labour can afford to be far more ambitious with its economic policies – voters are on board
Sudan: civil war stretches into a second year with no end in sight